Reading MASS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MASS free→Reading MASS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MASS free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, which may affect future performance. Peer multiples imply a price about 8% below where it trades (it looks expensive on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $8.62. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $8.62 MASS trades at 6× p/s — 1.9× the 3× p/s peer median. The market is re-rating it beyond its own range; our $7.74 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 11% near-term growth, in line with our forecast of about 8%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.21x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.14 → $-0.14 (+0.0% / 30d). 0 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$222.
How much price usually moves either way.
On a bad day, this stock has moved -$602.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,437.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare revenue growth speeds up, it could lift 908 Devices' prospects. This would signal a healthier market environment.
Confirms:Healthcare sector revenue growth speeds up toward 10% or more.
Disproves:Healthcare sector revenue growth keeps slowing down below current levels.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MASS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MASS 908 Devices, Inc. | Typical Show detailsSector percentile: 54 of 100 | full | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Targeting full year 2026 revenue growth between 19% and 25% compared to 2025.
Stated in 2 of last 2 quarters. 2026 revenue guidance increased from $64.5-$67.5M to $67.0-$70.0M, indicating a target growth of 19% to 25% over 2025. Revenue in 2026-Q1 was $13.38M, down from $17.38M in 2025-Q4, showing limited progress towards the annual target.
“908 Devices now expects full year 2026 revenues to be in the range of $67.0 million to $70.0 million.”
“908 Devices expects full year 2026 revenues to be in the range of $64.5 million to $67.5 million.”
Completed acquisition of NIRLAB Group to enhance product offerings and market reach.
Newly stated in 2026-Q1. The acquisition of NIRLAB Group was completed to enhance product offerings and market reach. This strategic move is expected to contribute to future growth, although immediate financial impact is not yet reflected in the current quarter's revenue of $13.38M.
“908 Devices completed its acquisition of NIRLAB SA and its subsidiary.”
Aiming to improve operating income through strategic initiatives and cost management.
Stated in 2 of last 2 quarters. Operating income fell from $3.09M in 2025-Q4 to -$12.88M in 2026-Q1, indicating a significant decline. Despite strategic initiatives, the trajectory shows limited progress in improving operating income.
Completion of Acquisition or Disposition of Assets. The information set forth in
Entry into a Material Definitive Agreement. Share Purchase Agreement On May 4, 2026 (the “Closing Date”), 908 Devices Inc. (the “Company”) completed its acquisition of NIRLAB SA, a corporation organized under the laws of Switzerland (“NIRLAB”), and its wholly owned subsidiary, NIRLAB Forensics Sàrl, a limited liability company organized under the laws of Switzerland (the “Subsidiary” and, together with NIRLAB, the “NIRLAB Group”), pursuant to a Share Purchase Agreement (the “Purchase Agreemen…
Pursuant to the terms of the Purchase Agreement and as set forth in Item 1.01, the Company issued or may issue Company Shares as Option Share Payment, Stock Consideration and Earn-Out Consideration (subject to the achievement of certain milestones set forth in the Purchase Agreement) (such Company Shares, the “Transaction Shares”). The Transaction Shares were or will be issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exempt…
Regulation FD Disclosure. On May 6 , 2026, the Company issued a press release announcing that it had entered into the Purchase Agreement. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K. Additionally, on May 6, 2026, 908 Devices posted an investor presentation regarding the acquisition of NIRLAB under the “Events & Presentations” section of its website. The information contained on or that can be accessed through the 908 Devices website is not incorp…
“Operating income was -$12.88M in 2026-Q1.”
“Operating income was $3.09M in 2025-Q4.”